2-苯甲酰-2,4-二氯乙酰苯胺 | 4016-85-7

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-苯甲酰-2,4-二氯乙酰苯胺
• 中文别名: 2-(2-氯乙酰胺)-5-氯二苯甲酮；2'-苯甲酰-2,4'-二氯乙酰苯胺；安定杂质
• 英文名称: 5-chloro-2-(chloroacetylamino)benzophenone
• 英文别名: N-(2-benzoyl-4-chlorophenyl)-2-chloroacetamide；2-Chloracetamino-5-chlor-benzophenon；2-(chloroacetamido)-5-chlorobenzophenone；2-(2-chloroacetamido)-5-chlorobenzophenone；2-Chloracetamido-5-chlorbenzophenon；5-Chlor-2-chloracetamino-benzophenon
• CAS: 4016-85-7
• 化学式: C₁₅H₁₁Cl₂NO₂
• mdl: MFCD00018905
• 分子量: 308.164
• InChiKey: HDXLZRWEZZFDKA-UHFFFAOYSA-N

物化性质

• 熔点：
  119-123 °C(lit.)
• 沸点：
  537.2±50.0 °C(Predicted)
• 密度：
  1.375
• 溶解度：
  可溶于氯仿（少量）、甲醇（轻微加热）
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 危险类别码：
  R34
• 危险品运输编号：
  UN 1759 8/PG 3
• WGK Germany：
  3
• RTECS号：
  AB4542650
• 海关编码：
  2924299090
• 安全说明：
  S26,S27,S36/37/39,S45
• 储存条件：
  请将药品存放在避光、通风干燥的地方，并密封保存。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: 2′-Benzoyl-2,4′-dichloroacetanilide
Product name
CAS-No. : 4016-85-7

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin corrosion (Category 1B)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Causes burns.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
Causes severe skin burns and eye damage.
Precautionary statement(s)
Wear protective gloves/ protective clothing/ eye protection/ face
protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Immediately call a POISON CENTER or doctor/ physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R34 Causes burns.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S27 Take off immediately all contaminated clothing.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards
Lachrymator.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C15H11Cl2NO2
Molecular Weight : 308,16 g/mol
Component Concentration
N-(2-Benzoyl-4-chlorophenyl)-2-chloroacetamide
CAS-No. 4016-85-7 -
EC-No. 223-678-1

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a
physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Cough, Shortness of breath, Headache, Nausea, Vomiting
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas. Moisture sensitive.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 119 - 123 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
LD50 Intraperitoneal - mouse - 1.000 mg/kg
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Material is extremely destructive to the tissue of
the mucous membranes and upper respiratory tract.
Ingestion May be harmful if swallowed. Causes burns.
Skin May be harmful if absorbed through skin. Causes skin burns.
Eyes Causes eye burns.
Signs and Symptoms of Exposure
Cough, Shortness of breath, Headache, Nausea, Vomiting
Additional Information
RTECS: AB4542650

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 1759 IMDG: 1759 IATA: 1759
UN proper shipping name
ADR/RID: CORROSIVE SOLID, N.O.S. (N-(2-Benzoyl-4-chlorophenyl)-2-chloroacetamide)
IMDG: CORROSIVE SOLID, N.O.S. (N-(2-Benzoyl-4-chlorophenyl)-2-chloroacetamide)
IATA: Corrosive solid, n.o.s. (N-(2-Benzoyl-4-chlorophenyl)-2-chloroacetamide)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯甲酰-2,4-二氯乙酰苯胺 在 盐酸 、 ammonium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 2.75h， 生成 去甲西泮
  参考文献：
  名称：

  咪唑啉丁-4-酮的合成及其转化为1,4-苯并二氮杂-2-酮

  摘要：

  α-卤代乙酰苯胺Ia-e与乙醇中的六胺反应，生成双咪唑啉丁-4-酮衍生物IIa-e，该衍生物在酸性介质中水解成相应的单咪唑啉丁-4-酮Ⅲa-e。在不同条件下，在多种试剂的存在下，化合物IIa-d被转化为1,4-苯并二氮杂-2-酮。产率在50％至100％之间。

  DOI：

  10.1002/jhet.5570180523
• 作为产物：
  描述：

  对氯苯胺 在 zinc(II) chloride 作用下， 以 甲苯 为溶剂， 反应 0.02h， 生成 2-苯甲酰-2,4-二氯乙酰苯胺
  参考文献：
  名称：

  含氮芥子基部分作为潜在中枢神经系统抗肿瘤剂的氨基二苯甲酮衍生物的设计，合成和评估

  摘要：

  合成了一系列含有氮芥子部分（5a - f）的新型取代氨基二苯甲酮衍生物，并根据其IR，1 H NMR，13 C NMR，CHN和质谱数据进行了表征。当评估4-（4-硝基苄基）吡啶烷基化化学活性时，所有化合物均证明是活性烷基化剂。通过计算，在线软件和QikProp 3.2对所有合成的化合物进行中枢神经系统（CNS）活动所需的理化参数测定。日志P值和分析的其他计算机模拟ADME理化指标位于良好BBB渗透所需的范围之间。对人癌细胞系的体外抗增殖活性。研究了549（肺），COLO 205（结肠），U 87（胶质母细胞瘤）和IMR-32（神经母细胞瘤）。大多数测试化合物显示出有效的抗肿瘤活性，尤其是化合物（5f）显示出最高的抗CNS癌细胞活性，与苯丁酸氮芥和多西紫杉醇相当。初步的构效关系（SAR）表明，5-氯氨基二苯甲酮-芥末系列（5a-c）比5-硝基氨基二苯甲酮-芥末系列（5d-f）表现出更好的抗肿瘤活性。

  DOI：

  10.1007/s00044-013-0582-8

文献信息

• Process for preparing benzodiazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US03996209A1

  公开（公告）日：1976-12-07

  1,4-Benzodiazepin-2-ones are prepared via the reaction of a haloacetamidophenyl ketone with hexamethylenetetramine in the presence of ammonia. The 1,4-benzodiazepin-2-ones so prepared are known compounds useful as muscle relaxant and anti-convulsant agents.

  1,4-苯二氮杂环己烷酮是通过在氨存在下，将卤代乙酰胺基苯酮与六亚甲基四胺反应制备而成。这种制备的1,4-苯二氮杂环己烷酮是已知的化合物，可用作肌肉松弛剂和抗惊厥药物。
• Synthesis and Antimicrobial Evaluation of 2-Aminobenzophenone Linked 1,4-Dihydropyridine Derivatives
  作者：Pengying Li、Ketki Sahore、Jianjun Liu、Rajesh K. Singh

  DOI：10.14233/ajchem.2014.17403

  日期：——

  A series of novel aminobenzophenone linked 1,4-dihydropyridines (1,4-DHPs) hybrids were synthesized by incorporating aminobenzophenone moiety on 1,4-dihydropyridines scaffold (5a-f) and characterized by IR, 1H NMR and CHN elemental analysis. The synthesized compounds were tested for their in vitro antibacterial activity against the Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Among all the synthesized compounds, compounds 5b, 5c and 5e have shown the maximum activity in their group whereas compounds 5a, 5d, 5f have shown the minimum activity.

  一系列新型氨基苯基酮连接的1,4-二氢吡啶（1,4-DHPs）杂合物通过在1,4-二氢吡啶骨架（5a-f）上引入氨基苯基酮部分合成而成，并通过红外光谱、氢谱（1H NMR）及CHN元素分析进行了表征。合成的化合物在体外测试了其对阳性菌（葡萄球菌）和阴性菌（大肠杆菌）的抗菌活性。在所有合成的化合物中，化合物5b、5c和5e显示出该组中的最大活性，而化合物5a、5d和5f则表现出最小活性。
• Process for preparing
  申请人：Pfizer Inc.

  公开号：US03932325A1

  公开（公告）日：1976-01-13

  A process is described for the preparation of 6-chloro-2-chloromethyl-4-phenylquinazoline-3-oxide, a key intermediate in the synthesis of the known useful psychotherapeutic agents: chlorodiazepoxide and diazepam. This intermediate is prepared by the cyclization of 2-(1'-chloroimino-2'-chloromethyl)-5-chlorobenzophenone, itself a new compound. This compound in turn is prepared by the chloroacetylation of 2-amino-5-chlorobenzophenone to 2-chloroacetamido-5-chlorobenzophenone, another novel compound, and subsequent iminochloride formation.

  描述了一种制备6-氯-2-氯甲基-4-苯基喹唑啉-3-氧的过程，这是合成已知有用的心理治疗药物氯二氮卓和安定的关键中间体。该中间体通过2-(1'-氯亚亚胺-2'-氯甲基)-5-氯苯基苯酮的环化制备，而这本身是一种新化合物。这种化合物又是通过2-氨基-5-氯苯基苯酮的氯乙酰化制备的，形成2-氯乙酰胺基-5-氯苯基苯酮，另一种新化合物，并随后形成亚胺氯化物。
• 一种地西泮药物中间体2-氯乙酰氨基-5-氯二苯酮的合成方法
  申请人：成都东电艾尔科技有限公司

  公开号：CN105541653A

  公开（公告）日：2016-05-04

  一种地西泮药物中间体2-氯乙酰氨基-5-氯二苯酮的合成方法，包括如下步骤：(i)在安装有搅拌器、温度计、回流冷凝器、滴液漏斗的反应容器中，加入2-氨基-5-氯-二苯酮(2)0.09mol，乙酸乙酯溶液300—350ml,控制搅拌速度120—160rpm,溶液温度27--30℃，滴加对氯乙酰苯胺0.11mol,加完后缓慢加热，使溶液温度维持在80--85℃，反应时间4—4.5h,然后降低溶液温度至5--8℃，析出黄色晶体，抽滤，乙二胺洗涤，盐溶液洗涤，脱水剂脱水，得2-氯乙酰氨基-5-氯二苯酮；其中，步骤(i)所述的乙酸乙酯溶液的质量分数为80—85％。
• Cyanoalkylamino-amido benzophenones
  申请人：Cassella Farbwerke Mainkur Akt

  公开号：US03950383A1

  公开（公告）日：1976-04-13

  The present invention relates to pharmacologically valuable new benzophenone derivatives having a pronounced sedative action on the central nervous system and some of which also possess muscle-relaxing and aggression-inhibiting properties. These new derivatives have the structural formula ##SPC1## And their addition salts, in which R.sub.1 and R.sub.2 are substituents selected from the group consisting of hydrogen, alkyl having 1-5 carbon atoms, alkenyl having 2 to 4 carbon atoms, alkinyl having 2 to 4 carbon atoms or .beta.-bromoallyl (--CH.sub.2 --CBr = CH.sub.2) ; R.sub.3 is --CN; n is an integer selected from 1 and 2; and m is an integer selected from 1, 2 and 3, wherein the rings A and B may be substituted, ring A being substituted preferably with a halogen such as chlorine or with nitro, trifluoromethyl, methyl, methoxy or methylmercapto, preferably in the 5 position, and ring B being preferably substituted in the 2' position with chlorine or fluorine. The radical R.sub.1 preferably signify hydrogen or a methyl, ethyl or propargyl group, the radicals for R.sub.2 preferably signify hydrogen or a methyl, allyl or an n-butyl group. C compounds represented by the above structural formula may be produced by reacting a compound represented by the formula ##SPC2## With a compound having the formula Y -- C.sub.m H.sub.2m -- R.sub.3, one of X and Y signifying the substituent R.sub.2 -- NH -- and the other signifying a halogen atom, preferably a bromine or chlorine atom, so as to form the above specified benzophenone derivative with the elimination of H -- Hal, R.sub.1, R.sub.2, R.sub.3, n and m being as defined above, and the rings A and B being optionally substituted as discussed above. The hydrogen halide which is eliminated is advantageously bound by the addition of an acid-binding agent, as for example, a molar excess of the amine used in the reaction or, for example, triethylamine, dimethylaniline, potassium or sodium carbonate or sodium bicarbonate. The reaction is carried out in a suitable solvent, preferably at an elevated temperature, typically the reflux temperature of the solvent used.

  本发明涉及具有明显镇静作用于中枢神经系统的药理学上有价值的新苯酮衍生物，其中一些还具有肌肉松弛和抑制攻击性质。这些新衍生物具有结构式##SPC1##及其加合盐，其中R.sub.1和R.sub.2是从氢，具有1-5个碳原子的烷基，具有2到4个碳原子的烯基，具有2到4个碳原子的炔基或.beta.-溴丙烯基（--CH.sub.2 --CBr = CH.sub.2）中选择的取代基；R.sub.3是--CN；n是选自1和2的整数；m是选自1、2和3的整数，其中环A和环B可以被取代，环A取代物最好是氯或硝基，三氟甲基，甲基，甲氧基或甲硫基，最好在5位，环B最好在2'位取代氯或氟。基团R.sub.1最好表示氢或甲基，乙基或丙炔基，基团R.sub.2最好表示氢或甲基，烯丙基或正丁基。上述结构式所代表的C化合物可以通过将由下式表示的化合物与具有下式Y -- C.sub.m H.sub.2m -- R.sub.3的化合物反应来制备，其中X和Y中的一个表示取代基R.sub.2 -- NH --，另一个表示卤原子，最好是溴或氯原子，以形成上述指定的苯酮衍生物，消除H -- Hal，R.sub.1，R.sub.2，R.sub.3，n和m如上所定义，环A和环B如上所述可能被取代。消除的氢卤酸可通过添加酸结合剂结合，例如，在反应中使用的胺的过量摩尔量，例如三乙胺，二甲苯胺，碳酸钾或碳酸钠。反应在适当的溶剂中进行，最好在升高的温度下进行，通常是所用溶剂的回流温度。